Table 5 Incremental cost-effectiveness ratio (expressed in euros per QALY) in the univariate analysis
Parameter value | Gemcitabine (n = 154) | Erlotinib (n = 155) |
|---|---|---|
Base case | 76,625 | 184,733 |
Gemcitabine tariff | ||
–30% | 47,132 | – |
Erlotinib tariff | ||
–30% | – | 125,957 |
Pemetrexed tariff | ||
–30% | 79,749 | 188,212 |
Palliative care cost | ||
€1,627 per month | 81,021 | 183,772 |
€3,021 per month | 72,213 | 185,680 |
Utility score under observation | ||
–10% | 117,197 | 307 149 |
+10% | 57,136 | 130,727 |
Utility score under IV chemotherapy | ||
–10% | €117,197 | – |
+10% | €57,136 | – |
Utility score under oral chemotherapy | ||
–10% | – | €366,092 |
+10% | – | €124,060 |